Ovarian cancer remains one of the most challenging gynaecological malignancies worldwide.1,2 Despite advances in first-line treatment, most patients with advanced disease will experience recurrence, and many will ultimately develop platinum-resistant ovarian cancer (PROC).3–6
An educational webinar organised and funded by AbbVie brought together leading oncology and pathology experts to discuss the evolving role of folate receptor alpha (FRα) in PROC. The session explored the clinical significance of FRα as a predictive biomarker,7 the emerging role of ELAHERE (mirvetuximab soravtansine),8 and practical considerations for implementing FRα testing into routine UK clinical practice.
With NICE recommending mirvetuximab soravtansine for eligible patients with FRα-positive PROC, in line with its licensed indication and in accordance with the commercial arrangement,9 this is an important time to revisit the key discussions and practical insights shared during the webinar.
Below, you can access a summary of the webinar alongside the on-demand video content to refresh your knowledge or catch up on the sessions you may have missed.
Abbreviations
ADC, antibody-drug conjugate; BRCA, breast cancer susceptibility gene 1; CPD, continuing professional development; FFPE, formalin-fixed paraffin-embedded; FRα, folate receptor-alpha; HRD, homologous recombination deficiency; NICE, National Institute of Health and Care Excellence; PROC, platinum-resistant ovarian cancer; SmPC, summary of product characteristics.
References
- Hanker LC, et al. Ann Oncol. 2012;23(10):2605-2612.
- González-Martín A, et al. Ann Oncol. 2023;34(10):833-848.
- Ke Xu, et al. Expert Rev Clin Pharmacol. 2023;16(11):1141-1152.
- Giornelli GH. Springerplus. 2016;5(1):1197.
- Salani R, et al. Am J Obstet Gynecol. 2011;204(6):466-478.
- St Laurent J and Liu JF. J Clin Oncol. 2024;42(2):127-133.
- Zannoni GF, et al. Int J Mol Sci. 2025;26(11):5222.
- ELAHERE SmPC.
- NICE. Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. TA1169. Available from: https://www.nice.org.uk/guidance/ta1169 [Accessed November 2026].
- Colombo N et al. Ann Oncol. 2019;30(5):672-705.
- Richardson DL, et al. JAMA Oncol. 2023;9(6):851-859.
- Gaillard S, et al. Gynecol Oncol. 2021;163(2):237-245.
- Pujade-Lauraine E, et al. J Clin Oncol. 2014;32(13):1302-1308.
- Poveda AM, et al. J Clin Oncol. 2015;33(32):3836-3838.
- Birrer MJ, et al. Oncologist. 2019;24(4):425-429.
- Scaranti M, et al. Nat Rev Clin Oncol. 2020;17(6):349-359.
- Köbel M, et al. Br J Cancer. 2014;111(12):2297-2307.
- Despierre E, et al. Gynecol Oncol. 2013;130(1):192-199.
- Rubinsak LA, et al. Appl Immunohistochem Mol Morphol. 2018;26(8):567-572.
- Ab O et al. Mol Cancer Ther. 2015;14(7):1605-1613.
- Moore K et al. Cancer. 2017;35(10):1112-1118.
- Fu Z et al. Sig Transduct Target Ther. 2022;7:93.
- Moore KN, et al. Ann Oncol. 2021;32:757-765.
- Moore KN, et al. N Engl J Med. 2023;389(23):2162-2174.
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer V.4.2026. April 10, 2026 [Accessed November 2026].
- Zannoni GF, et al. Int J Mol Sci. 2025;26(11):5222.
- Martin LP, et al. Gynecol Oncol. 2017;147(2):402-407.
- VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. Interpretation guide for epithelial ovarian, fallopian tube, or primary peritoneal cancer. VENTANA Medical Systems Inc/Roche Diagnostics International Inc; 2025.
- Based on speaker’s own experience and practice.
- Krivak T, et al. American Society of Clinical Oncology (ASCO) Annual Meeting. 2025. Poster 466.
- Cecere SC, et al. ESGO 2026. Oral presentation.
UK-ELAH-260249. Date of Preparation: November 2026
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
By clicking the link above, you will leave the AbbVie Pro website and be taken to the eMC PI portal website.